GlassScriptPhysician profile
Steven C Fowler
NPI 1619927126
$7,615.23
in general payments reported to CMS, 2019-2025
36 companies · $555 in 2025
The $555 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $730 · 2020: $957 · 2021: $1,345 · 2022: $1,165 · 2023: $1,381 · 2024: $1,483 · 2025: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,418.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,107.46 | 2019-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $1,103.63 | 2019-2025 | |
| Novo Nordisk INC | $708.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $635.76 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $450.77 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $434.24 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $403.58 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $355.35 | 2019-2023 | Eliquis |
| Exact Sciences Corporation | $334.72 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $258.17 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $223.35 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.26 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Allergan, INC. | $168.56 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $139.37 | 2019-2022 | |
| Astellas Pharma US INC | $138.18 | 2019-2024 | Veozah, Myrbetriq |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $121.95 | 2022 | |
| Dexcom, INC. | $109.18 | 2022-2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $106.22 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $91.84 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $78.95 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $64.77 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $60.28 | 2022-2023 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $58.99 | 2020-2021 | |
| Lexicon Pharmaceuticals, INC. | $43.34 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.83 | 2021 | |
| Amarin Pharma, INC. | $30.56 | 2020 | |
| Mylan Specialty L.P. | $26.60 | 2022-2023 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $26.15 | 2021-2022 | |
| Harmony Biosciences LLC | $18.61 | 2024 | |
| Alfasigma USA, INC. | $15.74 | 2020 | |
| Corcept Therapeutics | $14.47 | 2022 | |
| Abbott Laboratories | $13.31 | 2021 | |
| Almatica Pharma LLC | $13.24 | 2022 | |
| Inogen, INC. | $12.77 | 2022 | |
| Medicure Pharma INC. | $12.60 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $12.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Fowler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.